STCube, Inc. (KOSDAQ: 052020)

Market Cap	235.31B
Revenue (ttm)	7.66B
Net Income (ttm)	-22.12B
Shares Out	46.97M
EPS (ttm)	-474.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,601
Open	5,050.00
Previous Close	5,100.00
Day's Range	5,000.00 - 5,140.00
52-Week Range	4,350.00 - 14,400.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About STCube

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pi...

• Industry: Electronic Parts and Equipment, not elsewhere classified
• Founded: 1989
• Employees: 15
• Stock Exchange: KOSDAQ
• Ticker Symbol: 052020

Financial Performance

In 2023, STCube's revenue was 5.83 billion, a decrease of -7.54% compared to the previous year's 6.30 billion. Losses were -24.34 billion, 28.7% more than in 2022.